Fidelity Investments’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-183,229
Closed -$13.2M 5543
2025
Q4
$13.2M Sell
183,229
-21,402,755
-99% -$1.38B ﹤0.01% 1923
2025
Q3
$941M Buy
21,585,984
+5,400,193
+33% +$218M 0.05% 309
2025
Q2
$460M Buy
16,185,791
+570,727
+4% +$17M 0.03% 513
2025
Q1
$461M Sell
15,615,064
-894,542
-5% -$27.9M 0.03% 487
2024
Q4
$480M Sell
16,509,606
-339,170
-2% -$14.2M 0.03% 482
2024
Q3
$774M Buy
16,848,776
+689,729
+4% +$29.9M 0.05% 342
2024
Q2
$660M Buy
16,159,047
+1,917,411
+13% +$55M 0.04% 352
2024
Q1
$363M Buy
14,241,636
+3,837,540
+37% +$60.1M 0.02% 559
2023
Q4
$94.2M Sell
10,404,096
-710,335
-6% -$4.75M 0.01% 1038
2023
Q3
$70.9M Buy
11,114,431
+491,567
+5% +$4.24M 0.01% 1116
2023
Q2
$118M Buy
10,622,864
+5,203,807
+96% +$65.3M 0.01% 918
2023
Q1
$83.2M Buy
5,419,057
+493,679
+10% +$10.9M 0.01% 1049
2022
Q4
$109M Buy
4,925,378
+1,453,059
+42% +$21.7M 0.01% 937
2022
Q3
$56.7M Sell
3,472,319
-336,804
-9% -$6.44M 0.01% 1200
2022
Q2
$55.3M Sell
3,809,123
-1,792
-0% -$26.7K 0.01% 1214
2022
Q1
$70.4M Buy
3,810,915
+34,391
+0.9% +$584K 0.01% 1247
2021
Q4
$89.8M Sell
3,776,524
-57,143
-1% -$1.36M 0.01% 1150
2021
Q3
$94.4M Buy
3,833,667
+439,352
+13% +$9.55M 0.01% 1129
2021
Q2
$83.9M Sell
3,394,315
-39,273
-1% -$914K 0.01% 1199
2021
Q1
$74.9M Buy
3,433,588
+9,453
+0.3% +$231K 0.01% 1207
2020
Q4
$87.4M Buy
3,424,135
+405,304
+13% +$11.8M 0.01% 1092
2020
Q3
$85M Buy
3,018,831
+185,979
+7% +$5.37M 0.01% 988
2020
Q2
$80.1M Buy
+2,832,852
New +$81.7M 0.01% 974

Other funds holding RNAM

Fidelity Investments's RNAM Position: Q1 2026 in Review

Fidelity Investments sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 183,229 shares — an estimated $13.2M sold.

Fidelity Investments first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $941M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Fidelity Investments reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 183,229 Avidity Biosciences shares in Q1 2026, an estimated $13.2M.
  • Fidelity Investments first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
  • Fidelity Investments's Avidity Biosciences position peaked at $941M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.